Astria Therapeutics (NASDAQ:ATXS) Announces Quarterly Earnings Results

Astria Therapeutics (NASDAQ:ATXS) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01, Zacks reports.

Astria Therapeutics Stock Performance

Shares of ATXS traded up $0.01 during mid-day trading on Tuesday, hitting $5.83. The company’s stock had a trading volume of 20,583 shares, compared to its average volume of 258,663. The firm has a market capitalization of $329.01 million, a PE ratio of -2.79 and a beta of 0.69. Astria Therapeutics has a one year low of $5.75 and a one year high of $16.90. The stock’s 50-day moving average is $7.32 and its two-hundred day moving average is $9.65.

Analyst Ratings Changes

A number of research firms have recently weighed in on ATXS. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Thursday, February 27th. JMP Securities initiated coverage on Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 target price for the company. Finally, Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.